• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Monoclonal antibody L9LS prevents malaria infection in adults

byBryant LimandKiera Liblik
August 11, 2022
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this small phase one clinical trial, L9LS administration protected healthy adults from contracting a malarial infection.

2. No significant adverse events were observed in the L9LS group.

Evidence Rating Level: 2 (Good)

Study Rundown: Malaria is a life-threatening, mosquito-borne disease affecting millions worldwide. In regions of West Africa that are disproportionately affected by Malaria, the standard of care consists of seasonal chemoprevention and antimalarial drugs. However, these options are associated with low efficacy, drug resistance, and nonadherence issues. This phase one clinical trial evaluated the efficacy, safety, and pharmacokinetics of the new antimalarial monoclonal antibody, L9LS. L9LS was administered intravenously or subcutaneously. Participants were then exposed to malaria-positive mosquitoes for controlled infection and monitored for 21 days to assess for parasitemia before being given standard malaria treatment. L9LS was protective against controlled malaria infection, especially with higher doses. There were no severe adverse events associated with L9LS administration. Pharmacokinetic modeling from limited clinical data suggested that the effective dose of L9LS would remain in circulation for six months in participants who received the medication subcutaneously. As a limitation, the small sample size and study population (healthy adults in the United States) may reduce the generalizability of the efficacy and safety results to the Sub-Saharan African population that is most affected by malaria.

Click here to read the study in NEJM

In-Depth [randomized control trial]: In the present phase one clinical trial, healthy adults in the United States between 18 and 50 years of age received antimalarial monoclonal antibodies L9LS (n = 18) or a placebo control (n = 6). L9LS was administered intravenously (1 mg per kg (n = 5), 5 mg per kg (n = 4), or 20 mg per kg (n = 4)) or subcutaneously at 5 mg per kg (n = 5). Participants then underwent controlled human malarial infection and were monitored for 21 days for parasitemia as determined by polymerase-chain-reaction (PCR) test. After this initial period, patients were given the standard malarial treatment, followed by a 24- and seven-week observation for the L9LS and control groups, respectively. Parasitemia developed in two of the 17 L9LS participants and in all six control participants. For safety, solicited symptoms were mild or moderate in severity and self-limiting. One unsolicited adverse event, a case of mild cervical lymphadenopathy, occurred in a participant who received 1 mg per kg L9LS intravenously, which was resolved after 29 days without intervention. Pharmacokinetic modeling from limited clinical data showed that serum L9LS concentration maintained in the range of 5 to 11 microgram per milliliter after six months in participants who received 5 mg per kg L9LS subcutaneously, suggesting prolonged protection against malaria. The current trial is a proof of principle for a new prevention strategy for malaria. Still, further randomized control studies with a larger and more representative cohort are necessary to determine the efficacy and safety of L9LS.

Image: PD

RELATED REPORTS

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic diseaseinfectious diseaseL9LSmalariamosquitoneglected tropical diseasespreventative medicinepreventionpublic health
Previous Post

Breast density increases the risk of cancer and hinders mammographic detection [Classics Series]

Next Post

MRI offers an alternative to endoscopic assessment of disease activity and severity in ileocolonic Crohn’s disease [Classics Series]

RelatedReports

Social networks play key roles in parental vaccination decisions
Infectious Disease

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

January 30, 2023
Romosozumab significantly increases bone mineral density in postmenopausal women
Chronic Disease

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

January 30, 2023
Resection of colorectal liver metastases may improve cost and longevity
Chronic Disease

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

January 30, 2023
β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

January 27, 2023
Next Post
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

MRI offers an alternative to endoscopic assessment of disease activity and severity in ileocolonic Crohn’s disease [Classics Series]

Radiofrequency catheter ablation effective as first-line therapy for atrial fibrillation [RAAFT-2 trial]

Postoperative and nonoperative atrial fibrillation have a similar risk of associated thromboembolism

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Baricitinib reduces mortality risk in patients hospitalized with COVID-19

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients
  • #VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
  • Habitual social media use may alter neurodevelopment in adolescents
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options